At Signal12 Inc., we are committed to advancing knowledge about complex medical conditions that impact quality of life, such as ocular graft-versus-host disease (oGVHD). This condition, a significant complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT), affects approximately 40-60% of transplant recipients, manifesting as a debilitating ocular surface disorder. oGVHD arises when donor immune cells […]

Ocular graft-versus-host disease (oGVHD) transforms the eyes into battlegrounds of immune dysregulation post-allo-HSCT, necessitating robust therapeutic strategies. From topical agents to surgical interventions, management has evolved significantly, yet no single approach universally halts progression. This post surveys the therapeutic landscape, emphasizing evidence-based options and cutting-edge developments as of 2025. Topical Treatments First-line therapy targets inflammation […]

Ocular graft-versus-host disease (oGVHD) eludes early detection with traditional tools, driving the search for reliable biomarkers. These molecular signatures, detectable in tears or tissue, promise precision in diagnosing and monitoring this post-allo-HSCT complication. Recent advances in proteomics and cytokine profiling have illuminated oGVHD’s inflammatory underpinnings, offering a path to personalized care. This post explores key […]

Preventing ocular graft-versus-host disease (oGVHD) could spare allo-HSCT patients significant morbidity, yet proactive strategies remain underexplored. Pre- and post-transplant interventions targeting risk factors and early inflammation offer hope. This post evaluates evidence-based prevention approaches, grounded in current science. Pre-Transplant Strategies Conditioning regimens (e.g., cyclophosphamide, irradiation) damage ocular tissues, increasing oGVHD risk. Reduced-intensity conditioning (RIC) lowers […]

Ocular graft-versus-host disease (oGVHD) research is at a cusp, with innovations in genomics, immunotherapy, and modeling poised to reshape understanding and treatment. This post explores these horizons, spotlighting 2025’s most promising advances. Genomic Insights Gene expression profiling (e.g., HLA-G upregulation) could predict oGVHD risk. A 2024 Nature Communications study linked polymorphisms in IL-10 to lower […]